HC-Ad vectors: High-capacity adenoviral vectors

  • High‐Capacity adenoviral vectors (HC‐Ad), also called helper‐dependent or ‘gutless' are a new class of gene therapy vectors that allow stable transfer of large DNA fragments in vivo.

  • A new method for production of high‐quality HC‐Ad with potential applications in humans has been developed, based on a self‐inactivating adenovirus acting as a helper virus (HV).

  • Indications: monogenic diseases, cancer, liver cirrhosis and metabolic diseases.

>> Download information

Gene therapy product for Acute Intermittent Porphyria: Phase I Clinical trial

  • Adenoassociated viral (AAV) vectors are very promising tools for therapeutic gene delivery, since they are safe and they induce an efficient and long‐term transduction.

  • In collaboration with uniQure a gene therapy product for the treatment of Acute Intermittent Porphyria has been developed and is currently being evaluated in phase I clinical trial.

  • A new AAV expression system has been developed and an AAV production system has been  optimized.

    • AAV tetracycline‐inducible system  

    • liver and brain specific expression.

>> Download information


Research Programs

Research programs in which you can participate with CIMA

CIMA Research Programs and Agreements [PDF]

"CIMA Lab Diagnostics"


Its objective is to optimize the range of genetic and immunophenotypic diagnoses carried out in different laboratories of the University of Navarra with the highest level of quality and innovation.

Go to companies

Contact us:

Contact:
Center for Applied Medical Research (CIMA)
Avenida Pío XII, 55
31008 Pamplona
Spain

+34 948 194700
cima@unav.es